Regulatory T-cell induction pathway

The regulatory T-cell induction pathway comprises the network of molecular signals, transcriptional regulators, and epigenetic events required to generate and maintain regulatory T cells (Tregs), a specialized subpopulation of CD4+ T cells responsible for immune suppression and tolerance. Induction is primarily dependent on the transcription factor FOXP3, whose expression integrates signals from transforming growth factor-beta (TGF-β), retinoic acid, and several other pathways. Key steps include TGF-β/Smad signaling, histone acetylation, and interactions with transcription factors such as NFAT, c-Rel, CREB, AP-1, and Foxo1/3. Other critical mechanisms are modulation of dendritic cells, cytolytic activity, secretion of anti-inflammatory cytokines (IL-10, IL-35), metabolic shifts (e.g., increased oxidative phosphorylation and reactive oxygen species management), and the expression of cell surface receptors (CD25/IL-2R, CTLA-4)[2][3][4][5][6]. Dysregulation of this pathway is implicated in diverse diseases, including autoimmune disorders (rheumatoid arthritis, type I diabetes), chronic inflammation, and cancer (tumoral immune escape)[2][4][5]. While the pathway itself is not a direct drug target, modulation of its components (e.g., blockers of TGF-β, CTLA-4, or metabolic enzymes) is a major focus of immunotherapeutic development. Safety concerns with targeting this pathway include the risk of breaking immune tolerance, leading to autoimmunity, or exacerbating immunosuppression in cancer and infection settings[4][5].

Other names

Regulatory T cell differentiation pathwayTreg induction pathwayFoxp3 induction pathway